Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PPD shareholders approve $3.9 billion acquisition

This article was originally published in Scrip

Executive Summary

Shareholders of the CRO PPD have approved the $3.9 billion acquisition by the private equity companies Carlyle Group and Hellman & Friedman. Approximately 96.4% of shareholders voted in favour, and will receive $33.25 in cash for each share of the company's common stock they own.

You may also be interested in...



Hoops, hoopla, big ideas and diabetes

Perhaps only a man who inherited an enthusiasm for peptides could, without a trace of irony, cast diabetes drug development as the work of a pastry chef. But for David Solomon, the son of a peptide devotee, mixed metaphors and stretched comparisons are simply the spray thrown up by his unbridled enthusiasm for his chosen trade, that of basketball coach to GLP-1 receptor agonist developer Zealand Pharma.

Scrip Asia 100 league tables 2013

How Dennis Gillings took a gamble and built a $3.7bn business

"How the hell will Glaxo need you? You've only got a few people, they've got about 50,000!"

Related Companies

UsernamePublicRestriction

Register

OM002409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel